Follow-up surveillance strategies for genitourinary malignancies

被引:12
作者
Evans, CP [1 ]
机构
[1] Univ Calif Davis, Dept Urol, Sch Med, Sacramento, CA 95817 USA
关键词
urologic cancer follow-up; prostate cancer; bladder cancer; renal cell cancer; testicular cancer; cancer surveillance;
D O I
10.1002/cncr.10525
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. Genitourinary cancers account for more than 20% of all malignancies in the United States. These cancers do not usually yield rapid mortality, thereby necessitating longer-term surveillance strategies. METHODS. A review and analysis of relevant studies were performed, Follow-up strategies are proposed to reflect effective methods to detect recurrent prostate, bladder, renal, and testicular cancers. Cost analysis was performed using Medicare reimbursement rates. RESULTS. For genitourinary tumors, follow-up tests can be planned rationally based on detection rates and patterns. Tumor grade and stage drive follow-up strategies, along with therapeutic implications of detecting a recurrence. Symptomatic recurrences often obviate the need for radiographic tests and can minimize costs. Stage-specific plans for these four urologic malignancies are outlined specifically. CONCLUSIONS. Not all surveillance approaches have been critically tested for follow-up of genitourinary tumors, but ample data are available to propose sound medical and economic strategies. (C) 2002 American Cancer Society.
引用
收藏
页码:2892 / 2905
页数:14
相关论文
共 67 条
[61]   Risk of second malignant neoplasms among long-term survivors of testicular cancer [J].
Travis, LB ;
Curtis, RE ;
Storm, H ;
Hall, P ;
Holowaty, E ;
VanLeeuwen, FE ;
Kohler, BA ;
Pukkala, E ;
Lynch, CF ;
Andersson, M ;
Bergfeldt, K ;
Clarke, EA ;
Wiklund, T ;
Stoter, G ;
Gospodarowicz, M ;
Sturgeon, J ;
Fraumeni, JF ;
Boice, JD .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (19) :1429-1439
[62]  
Tsai DY, 1999, CANCER, V86, P1314, DOI 10.1002/(SICI)1097-0142(19991001)86:7<1314::AID-CNCR29>3.0.CO
[63]  
2-K
[64]   Bladder wash cytology, quantitative cytology, and the qualitative BTA test in patients with superficial bladder cancer [J].
Van der Poel, HG ;
Van Balken, MR ;
Schamhart, DHJ ;
Peelen, P ;
de Reijke, T ;
Debruyne, FMJ ;
Schalken, JA ;
Witjes, JA .
UROLOGY, 1998, 51 (01) :44-50
[65]   Radiotherapy for PSA recurrence after radical prostatectomy [J].
Vanuytsel, L ;
Janssens, G ;
Van Poppel, H ;
Rijnders, A ;
Baert, L .
EUROPEAN UROLOGY, 2001, 39 (04) :425-429
[66]   IDENTIFYING PATIENTS WITH LOW-RISK CLINICAL STAGE-I NONSEMINOMATOUS TESTICULAR-TUMORS WHO SHOULD BE TREATED BY SURVEILLANCE [J].
WISHNOW, KI ;
DUNPHY, CH ;
JOHNSON, DE ;
AYALA, AG ;
SWANSON, DA ;
RO, JY ;
TENNEY, DM ;
VONESCHENBACH, AC ;
BABAIAN, RJ .
UROLOGY, 1989, 34 (06) :339-343
[67]   Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer [J].
Zagars, GK ;
Pollack, A ;
von Eschenbach, AC .
UROLOGY, 2001, 58 (02) :233-239